1. Home
  2. XGN vs ATRA Comparison

XGN vs ATRA Comparison

Compare XGN & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$2.67

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Logo Atara Biotherapeutics Inc.

ATRA

Atara Biotherapeutics Inc.

HOLD

Current Price

$4.69

Market Cap

38.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XGN
ATRA
Founded
2002
2012
Country
United States
United States
Employees
220
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.5M
38.9M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
XGN
ATRA
Price
$2.67
$4.69
Analyst Decision
Strong Buy
Hold
Analyst Count
7
1
Target Price
$9.14
$6.00
AVG Volume (30 Days)
288.5K
270.3K
Earning Date
03-10-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
122.52
EPS
N/A
2.57
Revenue
N/A
$120,772,000.00
Revenue This Year
$8.06
N/A
Revenue Next Year
$12.93
N/A
P/E Ratio
N/A
$1.83
Revenue Growth
N/A
N/A
52 Week Low
$2.65
$3.92
52 Week High
$12.23
$19.15

Technical Indicators

Market Signals
Indicator
XGN
ATRA
Relative Strength Index (RSI) 30.03 40.10
Support Level N/A $4.06
Resistance Level $3.89 $5.80
Average True Range (ATR) 0.23 0.58
MACD -0.00 -0.06
Stochastic Oscillator 3.46 0.00

Price Performance

Historical Comparison
XGN
ATRA

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

About ATRA Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Share on Social Networks: